Anti-viral T-cell Therapy by Gamma Capture
At a glance
Conditions
NCT06027879
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvaniano site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Paul Szabolcs, MD · PRINCIPAL_INVESTIGATOR · University of Pittsburgh
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Grade III-IV Acute GvHDDay 0
The number of patients who develop Grade III-IV acute graft versus host disease (GVHD) attributed to the viral specific T cells.
- Grade III-IV Acute GvHD1 month from first cellular infusion
The number of patients who develop Grade III-IV acute graft versus host disease (GVHD) attributed to the viral specific T cells.
- Grade III-IV Acute GvHD3 month from first cellular infusion
The number of patients who develop Grade III-IV acute graft versus host disease (GVHD) attributed to the viral specific T cells.
- Grade III-IV Acute GvHD6 month from first cellular infusion
The number of patients who develop Grade III-IV acute graft versus host disease (GVHD) attributed to the viral specific T cells.
- Clinical response to treatment of viral infection1 month from first cellular infusion
Rate of Elimination or reduction of oxygen dependence identified at baseline
- Clinical response to treatment of viral infection1 month from first cellular infusion
Rate of Resolution of diarrhea attributable to the viral disease, less than 4 stools daily
- Clinical response to treatment of viral infection1 month from first cellular infusion
Rate of Resolution of fever, attributable to viral disease
- Clinical response to treatment of viral infection1 month from first cellular infusion
Rate of Resolution or improvement of radiographic findings attributable to viral disease
- Clinical response to treatment of viral infection1 month from first cellular infusion
Rate of Resolution or improvement of lymphadenopathy attributable to EBV, and ophthalmic findings attributable to CMV retinitis
- Clinical response to treatment of viral infection3 month from first cellular infusion
Rate of Elimination or reduction of oxygen dependence identified at baseline
- Clinical response to treatment of viral infection3 month from first cellular infusion
Rate of Resolution of diarrhea attributable to the viral disease, less than 4 stools daily
- Clinical response to treatment of viral infection3 month from first cellular infusion
Rate of Resolution of fever, attributable to viral disease
- Clinical response to treatment of viral infection3 month from first cellular infusion
Rate of Resolution or improvement of radiographic findings attributable to viral disease
- Clinical response to treatment of viral infection3 month from first cellular infusion
Rate of Resolution or improvement of lymphadenopathy attributable to EBV, and ophthalmic findings attributable to CMV retinitis
- Clinical response to treatment of viral infection6 months from first cellular infusion
Rate of Elimination or reduction of oxygen dependence identified at baseline
- Clinical response to treatment of viral infection6 months from first cellular infusion
Rate of Resolution of diarrhea attributable to the viral disease, less than 4 stools daily
- Clinical response to treatment of viral infection6 months from first cellular infusion
Rate of Resolution of fever, attributable to viral disease
- Clinical response to treatment of viral infection6 months from first cellular infusion
Rate of Resolution or improvement of radiographic findings attributable to viral disease
- Clinical response to treatment of viral infection6 months from first cellular infusion
Rate of Resolution or improvement of lymphadenopathy attributable to EBV, and ophthalmic findings attributable to CMV retinitis